UPDATES IN MEDICINE

2022-03-23 02:21:32 ​​ Iberdomide in Systemic Lupus Erythematosus


In a phase 2 trial of iberdomide in patients with moderate-to-severe SLE, a composite response (on the Systemic Lupus Erythematosus Responder Index–4) occurred in 54% of those who received iberdomide (0.45 mg), as compared with 35% in the placebo group, but this between-group difference was not significant at lower doses. Urinary tract and respiratory tract infections and neutropenia occurred.


@Updates_in_Medicine Open / Comment

2022-03-22 02:28:46 ​​WHO guidelines on Management of tuberculosis in children and adolescents - March 2022

@Updates_in_Medicine Open / Comment

2022-03-19 10:22:10 @Updates_in_Medicine Open / Comment

2022-03-19 10:20:45 ​​ Prekallikrein and Hereditary Angioedema

Hereditary angioedema with C1 inhibitor deficiency, characterized by unpredictable and occasionally fatal swellings, is caused by uncontrolled activity of factor XIIa and plasma kallikrein, leading to locally increased vascular permeability. In a small, randomized, controlled trial, an antisense oligonucleotide drug targeting prekallikrein suppressed attacks by 90% over a 17-week period.

@Updates_in_Medicine Open / Comment

2022-03-16 12:05:28 Join GLOBAL SCIENCE FORUM

Latest scientific discoveries, Space, Environment, Technology and many more....


https://t.me/Global_Science_Forum Open / Comment

2022-03-16 03:05:10 ​​ ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment


@Updates_in_Medicine Open / Comment